晚期血液系统恶性肿瘤患者接受嵌合抗原受体T细胞治疗后的心血管事件:一项Meta分析
该Meta分析系统检索MEDLINE、Embase、Cochrane Library和Google Scholar(建库至2024年2月26日),纳入13项观察性研究、1528例接受CAR T细胞治疗的晚期血液系统恶性肿瘤成人患者(中位年龄61岁,66%为男性,80%为淋巴瘤),中位随访487天。随机效应模型合并的患病率:室性心律失常0.66%(95%CI 0.00%-2.28%)、室上性心律失常7.79%(95%CI 4.87%-11.27%)、左心室功能不全8.68%(95%CI 2.26%-17.97%)、心力衰竭事件3.87%(95%CI 1.77%-6.62%)、心肌梗死0.62%(95%CI 0.02%-1.74%)、心血管死亡0.63%(95%CI 0.13%-1.38%)、全因死亡30.01%(95%CI 19.49%-41.68%)。作者认为心血管监测策略应聚焦于射血分数下降和室上性心律失常。
要点
- 在接受CAR T细胞治疗的晚期血液系统恶性肿瘤成人中,左心室功能不全的合并患病率为8.68%(95%CI 2.26%-17.97%),为报告最多的心血管并发症之一。
- 室上性心律失常的合并患病率为7.79%(95%CI 4.87%-11.27%),是另一常见心血管并发症。
- 室性心律失常(0.66%,95%CI 0.00%-2.28%)、心肌梗死(0.62%,95%CI 0.02%-1.74%)和心血管死亡(0.63%,95%CI 0.13%-1.38%)的合并患病率均较低。
- 心力衰竭事件的合并患病率为3.87%(95%CI 1.77%-6.62%),全因死亡的合并患病率为30.01%(95%CI 19.49%-41.68%)。
- 作者认为,心血管监测策略应聚焦于射血分数下降和室上性心律失常。
适用人群与场景
- 成人(年龄≥18岁)接受CAR T细胞治疗晚期血液系统恶性肿瘤的患者;纳入的13项研究中80%为淋巴瘤患者,中位年龄61岁(IQR 58.7-63.0岁),66%为男性。
- 纳入标准:观察性研究,包含接受CAR T细胞治疗的成人晚期血液系统恶性肿瘤患者,并系统评估心血管并发症。
研究设计与关键结果
- 研究类型:系统评价与Meta分析(观察性研究),遵循MOOSE报告规范;共纳入13项观察性研究、1528例CAR T细胞治疗者;中位随访487天(IQR 294-530天)。
- 主要终点合并患病率(随机效应模型,Freeman-Tukey双反正弦变换):室性心律失常0.66%(95%CI 0.00%-2.28%),室上性心律失常7.79%(95%CI 4.87%-11.27%),左心室功能不全8.68%(95%CI 2.26%-17.97%),心力衰竭事件3.87%(95%CI 1.77%-6.62%),心肌梗死0.62%(95%CI 0.02%-1.74%),心血管死亡0.63%(95%CI 0.13%-1.38%),全因死亡30.01%(95%CI 19.49%-41.68%)。
- 敏感性分析(广义线性混合模型,logit变换)结果与主分析相似。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入观察性研究;未报告证据等级或推荐强度。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,心血管监测策略应聚焦于射血分数下降和室上性心律失常,因左心室功能不全和室上性心律失常是最常报告的心血管并发症。
- 该Meta分析发现短期至中期随访中室性心律失常、心肌梗死和心血管死亡的患病率较低,可能影响监测资源的分配。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The frequency and clinical phenotypes of cardiotoxic events in chimeric antigen receptor (CAR) T-cell recipients remain poorly understood given that landmark approval trials typically exclude patients with high-risk cardiovascular profiles and data from nontrial settings are scarce.
OBJECTIVE: To summarize the prevalence of adverse cardiovascular events among adults receiving CAR T-cell therapies for advanced hematologic malignant neoplasms.
DATA SOURCES: MEDLINE, Embase, Cochrane Library, and Google Scholar were systematically searched from database inception until February 26, 2024.
STUDY SELECTION: Observational studies were included if they comprised adult CAR T-cell recipients with advanced hematologic malignant neoplasms and if they systematically evaluated cardiovascular complications.
DATA EXTRACTION AND SYNTHESIS: Extraction of prespecified parameters related to the patient population, study design, and clinical events was performed at the study level by 2 independent reviewers in accordance with the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) reporting guideline. Meta-analysis of single proportions was conducted using random-effect models with Freeman-Tukey double arcsine transformations to calculate pooled prevalence estimates. Sensitivity analysis was performed using generalized linear mixed models with logit transformations.
MAIN OUTCOMES AND MEASURES: Ventricular and supraventricular arrhythmias, heart failure events, reduction in left ventricular ejection fraction, myocardial infarction, and cardiovascular and all-cause mortality.
RESULTS: Thirteen studies comprising 1528 CAR T-cell recipients (median [IQR] age, 61 [58.7-63.0] years; 1016 males [66%]; 80% patients with lymphoma) were included. The median (IQR) duration of follow-up was 487 (294-530) days. On random-effects meta-analysis, we observed a pooled prevalence of 0.66% (95% CI, 0.00%-2.28%) for ventricular arrhythmia, 7.79% (95% CI, 4.87%-11.27%) for supraventricular arrhythmia, 8.68% (95% CI, 2.26%-17.97%) for left ventricular dysfunction, 3.87% (95% CI, 1.77%-6.62%) for heart failure events, 0.62% (95% CI, 0.02%-1.74%) for myocardial infarction, and 0.63% (95% CI, 0.13%-1.38%) for cardiovascular death. The pooled prevalence of all-cause mortality was 30.01% (95% CI, 19.49%-41.68%). Sensitivity analyses generated similar findings.
CONCLUSIONS AND RELEVANCE: This meta-analysis found a low prevalence of ventricular arrhythmia, myocardial infarction, and cardiovascular death among CAR T-cell recipients over a short-term to midterm follow-up. Left ventricular dysfunction and supraventricular arrhythmia were the most commonly reported cardiovascular complications, suggesting that cardiovascular surveillance strategies should focus on decreases in ejection fraction and supraventricular arrhythmia.
参考来源
- Koeckerling D, Reddy RK, Barker J, et al. Cardiovascular Events After Chimeric Antigen Receptor T-Cell Therapy for Advanced Hematologic Malignant Neoplasms: A Meta-Analysis. JAMA Netw Open. 2024. PMID: 39374017. doi:10.1001/jamanetworkopen.2024.37222
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。